Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Guardant Health’s 10-K can feel like wading through both biotech jargon and accounting footnotes. Key details on liquid biopsy test volumes, FDA submissions, and R&D burn rates are scattered across hundreds of pages, while Form 4 insider sales from the founders often appear without context. If you have ever searched “Guardant Health SEC filings explained simply� or asked, “Where can I find the Guardant Health quarterly earnings report 10-Q filing?�, you know the challenge.
Stock Titan solves it. Our AI-powered summaries translate dense cancer-genomics language into clear insights, flagging segment revenue shifts and clinical milestone disclosures in seconds. Need real-time alerts? The moment a “Guardant Health Form 4 insider transactions real-time� filing hits EDGAR, we surface it alongside easy-to-read charts of executive stock transactions. Drill into any document:
- Guardant Health annual report 10-K simplified � spot test-volume growth and cash runway.
- Guardant Health quarterly earnings report 10-Q filing � track sequential margin changes.
- Guardant Health 8-K material events explained � catch trial results or reimbursement wins.
- Guardant Health proxy statement executive compensation � review R&D-weighted incentive plans.
Whether you’re modeling future oncology revenues or monitoring “Guardant Health earnings report filing analysis� for competitive intelligence, Stock Titan provides AI guidance that saves hours. Join institutional investors who are already “understanding Guardant Health SEC documents with AI� to make informed decisions faster.
Guardant Health (GH) Form 4: Director Steve E. Krognes reported the automatic conversion of 154 restricted stock units (RSUs) into an equal number of common shares on 07/31/2025 (transaction code “M�). No shares were sold. The RSUs stem from an August 9 2022 grant that vested 25 % on 06/30/2023; the remaining 75 % continue to vest in equal monthly installments through mid-2026.
Following the conversion, Krognes now holds 17,973 shares directly and retains 1,698 un-settled RSUs. The transaction was priced at $0, indicating a standard equity award settlement rather than an open-market purchase. Ownership structure remains direct, and no 10b5-1 plan was indicated.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
